Fabuless® (Structured Lipid Emulsion)

Evidence Level
Preliminary
1 Clinical Trial
3 Documented Benefits
1/5 Evidence Score

Fabuless® (also sold as Olibra) is a structured emulsion of palm and oat oils designed to prolong fullness and reduce later food intake. The idea is that the special emulsion reaches the lower gut intact and triggers the body's natural appetite brake. Clinical results have been mixed, with some trials showing reduced intake and others showing no effect.

Studied Dose Around 5 grams of the emulsion before a meal.
Active Compound A structured oil-in-water emulsion of fractionated palm oil and oat oil.

Benefits

Satiety support (proposed, not confirmed in the cited trial)

Increased fullness and reduced intake at a later meal is the intended effect of this emulsion, but it is not demonstrated by the evidence cited here: the one randomized crossover trial on this page (Chan 2017, 18 lean men) tested the commercial product and found no change in short-term appetite or food intake. Earlier reports of reduced later-meal intake have not been consistently reproduced.

Appetite management

Extending the time between meals and curbing snacking is how Fabuless is marketed, not an outcome demonstrated by the evidence on this page. In the randomized crossover trial cited here, the commercial emulsion did not change short-term appetite or the amount eaten at the next meal.

Honest evidence note

Results across trials are mixed: several studies found no significant effect on appetite or weight, so benefits should be viewed with realistic expectations.

Mechanism of action

1

Ileal brake activation

The proposed mechanism is that the emulsion delivers fat to the lower small intestine intact and engages the ileal brake, a reflex that slows digestion and contributes to fullness. This is the design rationale for the product; in the human trial cited here it did not translate into a measurable appetite or food-intake effect.

2

Delayed fat digestion

Slower release of fatty acids is hypothesized to prolong satiety signaling from the gut to the brain. This remains a proposed mechanism and is not supported by an appetite or intake benefit in the trial cited on this page.

Clinical trials

1
Small Particle Size Lipid Emulsions and Satiety — Null Randomized Crossover
PubMed

Six-arm randomized crossover study of small particle size lipid emulsions, including the commercial Fabuless product, on acute satiety and energy intake in 18 lean men. (Chan et al. 2017, Physiology and Behavior)

18 lean men (small acute-feeding crossover; results may not apply to people with overweight or obesity).

This trial was null: the authors reported no evidence that the small particle size dairy lipid emulsions or the commercial Fabuless product altered short-term appetite or food intake in lean adults. It was a six-arm randomized crossover in 18 lean men, so it speaks to acute appetite only; across the wider literature, appetite and weight results have been mixed.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — digestive symptoms are most common.
Mild bloating or changes in bowel habit can occur.
Contains palm and oat oil.
Evidence for an appetite benefit is mixed and, for the branded product, weak: the one randomized trial cited on this page tested the commercial Fabuless emulsion and found no effect on short-term appetite or food intake.

Important Drug interactions

No major drug interactions are established for this ingredient.
Tell your doctor about all supplements if you take prescription medication.
Use caution if pregnant, breastfeeding, or managing a health condition.

Frequently asked questions about Fabuless® (Structured Lipid Emulsion)

What is Fabuless?

Fabuless® (also sold as Olibra) is a structured emulsion of palm and oat oils designed to prolong fullness and reduce later food intake. The idea is that the special emulsion reaches the lower gut intact and triggers the body's natural appetite brake.

What is Fabuless used for?

Fabuless is researched primarily for Weight Management. Increased fullness and reduced intake at a later meal is the intended effect of this emulsion, but it is not demonstrated by the evidence cited here: the one randomized crossover trial on this page (Chan 2017, 18 lean men) tested the commer…

What is the recommended dosage of Fabuless?

The clinically studied dose is Around 5 grams of the emulsion before a meal. Always follow the product label and check with a healthcare provider for personal advice.

Is Fabuless safe, and does it have side effects?

For most healthy adults, Fabuless is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — digestive symptoms are most common. Mild bloating or changes in bowel habit can occur. It may also interact with some medications. Fabuless is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Fabuless interact with any medications?

Possible interactions include: No major drug interactions are established for this ingredient. Tell your doctor about all supplements if you take prescription medication. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Fabuless?

NutraSmarts rates the evidence for Fabuless as Preliminary (1 out of 5). It is backed by 1 clinical trial and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Chan YK, Budgett SC, MacGibbon AK, et al. Small particle size lipid emulsions, satiety and energy intake in lean men. Physiol Behav. 2017;169:98-105..PubMedUsed to support: Six-arm randomized crossover in 18 lean men. Found no evidence that small particle size dairy lipid emulsions or commercial Fabuless altered short-term appetite or food intake. This is the only human trial cited on this page for the branded product, and it is a null result.